NCT03629756 2024-05-24A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesArcus Biosciences, Inc.Phase 1 Completed48 enrolled
NCT06155396 2024-02-28A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRemeGen Co., Ltd.Phase 2 Recruiting116 enrolled